Cardiac Biomarkers in Pediatric Cardiomyopathy

小儿心肌病的心脏生物标志物

• 批准号: 8295233
• 负责人: STEVEN EDWARD LIPSHULTZ
• 金额: $ 143.06万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-06 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8295233
• 关键词: Acute; Age-Years; Agreement; Applications Grants; Area; Biological Markers; Cardiac; Cardiomyopathies; Cessation of life; Child; Childhood; Clinical; Collagen; Developing Countries; Diagnosis; Dilated Cardiomyopathy; Disease; Early Diagnosis; Echocardiography; Familial Hypertrophic Cardiomyopathy; Fibrosis; Functional disorder; Heart Transplantation; Heart failure; Hypertrophic Cardiomyopathy; Hypertrophy; Left; Left Ventricular Mass; MRI Scans; Magnetic Resonance Imaging; Measurement; Measures; Metabolism; Myocardial; Myocardium; Newly Diagnosed; Outcome; Patients; Pediatrics; Research; Research Project Grants; Serum; Therapeutic; Time; Transplantation; Ventricular; clinical care; cost effective; evidence base; experience; improved; novel

DESCRIPTION (provided by applicant): This is a research project grant (R01) application for Cardiac Biomarkers in Pediatric Cardiomyopathy. In this grant proposal, there will be three specific aims. The first will attempt to determine the clinical importance of established and novel cardiac biomarkers in children with newly diagnosed (incident) dilated cardiomyopathy. The second will aim to assess the clinical utility of cardiac biomarkers of collagen metabolism in determining the presence of myocardial fibrosis, as established by cardiac MRI, and diastolic dysfunction, as established by echocardiography in both newly diagnosed and existing cases of idiopathic or familial hypertrophic cardiomyopathy in children. The third and final aim will focus on determining whether longitudinal changes in cardiac biomarkers are associated with worsening heart failure class in clinically stable children with dilated or hypertrophic cardiomyopathy. These studies will significantly increase our understanding of pediatric cardiomyopathy, suggest new areas of research, and improve patient management as it relates to determining the most appropriate evidence-based clinical care for pediatric cardiomyopathy patients. PUBLIC HEALTH RELEVANCE: Cardiomyopathies (diseases of the heart muscle) are a leading cause of heart failure, death, and heart transplantation in children, yet time to transplan or death for children with cardiomyopathy has not improved during the past 35 years, with the most economically advanced nations having no better outcomes than developing nations. The percentage of children with cardiomyopathy who received a heart transplant has not declined over the past 10 years and cardiomyopathy remains the leading cause of transplantation for children over one year of age. The Cardiac Biomarker in Pediatrics R01 will aim to identify specific cardiac biomarkers and panels of biomarkers that will help determine the most appropriate evidence- based clinical care for pediatric cardiomyopathy patients, including when to consider heart transplantation as a therapeutic option, and will offer the least invasive (a particularly important consideration in children) and most-cost-effective approach to the early detection of cardiac dysfunction.